Unknown

Dataset Information

0

RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.


ABSTRACT: Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.

SUBMITTER: Kakuta H 

PROVIDER: S-EPMC4025743 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates. ...[more]

Similar Datasets

| S-EPMC2094732 | biostudies-literature
| S-EPMC3671991 | biostudies-literature
| S-EPMC2693451 | biostudies-literature
| S-EPMC4695086 | biostudies-literature
| S-EPMC5940249 | biostudies-literature
| S-EPMC9462852 | biostudies-literature
| S-EPMC4007838 | biostudies-other
| S-EPMC6695845 | biostudies-literature
| S-EPMC10849508 | biostudies-literature
| S-EPMC5553648 | biostudies-other